Lorundrostat, a novel aldosterone synthase inhibitor developed by Mineralys Therapeutics, has demonstrated significant blood pressure reductions in two pivotal hypertension trials, according to the company’s announcement.
The drug targets uncontrolled and resistant hypertension, which affects approximately 20 million people in the U.S. alone.
Key Findings from the Launch-HTN Trial:
This phase 3, placebo-controlled trial involved 1,083 adults who remained hypertensive despite taking 2-5 antihypertensive medications.
- After 6 weeks, patients receiving 50 mg of lorundrostat experienced an absolute reduction of 16.9 mmHg and a placebo-adjusted reduction of 9.1 mmHg in systolic blood pressure.
- After 12 weeks, those on 50 mg continued to show improvements, with a 19.0 mmHg absolute reduction and an 11.7 mmHg placebo-adjusted reduction.
- Patients on 100 mg after 6 weeks showed an absolute reduction of 15.7 mmHg and placebo-adjusted reduction of 8.4 mmHg after 12 weeks.
Advance-HTN Trial Results:
- This phase 2 trial assessed lorundrostat as an add-on therapy in patients receiving standardized background antihypertensive treatment.
- At 12 weeks, 50 mg of lorundrostat resulted in a placebo-adjusted systolic blood pressure reduction of 7.9 mmHg (measured via 24-hour ambulatory monitoring).
Potential Impact on Hypertension Management:
Lorundrostat works by inhibiting CYP11B2, the enzyme responsible for aldosterone synthesis, reducing plasma aldosterone levels by approximately 70%."Reductions in blood pressure of this magnitude have been linked to significant decreases in overall cardiovascular risk," said Jon Congleton, CEO of Mineralys.
The full Advance-HTN trial results will be presented at the American College of Cardiology Scientific Session in Chicago on March 29.
These promising results position lorundrostat as a transformative treatment for patients with uncontrolled or resistant hypertension, offering a potential breakthrough in targeted blood pressure management.
